The Hemophilia B (Factor IX Deficiency) drugs in development market research report provides comprehensive information on the therapeutics under development for Hemophilia B (Factor IX Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemophilia B (Factor IX Deficiency). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemophilia B (Factor IX Deficiency) and features dormant and discontinued products.
GlobalData tracks 58 drugs in development for Hemophilia B (Factor IX Deficiency) by 54 companies/universities/institutes. The top development phase for Hemophilia B (Factor IX Deficiency) is preclinical with 26 drugs in that stage. The Hemophilia B (Factor IX Deficiency) pipeline has 49 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Hemophilia B (Factor IX Deficiency) pipeline products market are: Novo Nordisk, Gyre Therapeutics and Zhengzhou Gensciences.
The key targets in the Hemophilia B (Factor IX Deficiency) pipeline products market include Coagulation Factor IX, Coagulation Factor VII, and Tissue Factor Pathway Inhibitor.
The key mechanisms of action in the Hemophilia B (Factor IX Deficiency) pipeline product include Coagulation Factor IX Activator with 27 drugs in Pre-Registration. The Hemophilia B (Factor IX Deficiency) pipeline products include five routes of administration with the top ROA being Intravenous and 12 key molecule types in the Hemophilia B (Factor IX Deficiency) pipeline products market including Gene Therapy, and Monoclonal Antibody.
Hemophilia B (Factor IX Deficiency) overview
Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage, and nosebleeds. Treatment includes replacing the defective clotting factor.
For a complete picture of Hemophilia B (Factor IX Deficiency)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
